

This is a repository copy of *Identification of the Molecular Target of an Inducer of Human Glioblastoma Self-Destruction*.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/136300/

Version: Published Version

Proceedings Paper:

Bon, RS orcid.org/0000-0003-1733-3680 (2016) Identification of the Molecular Target of an Inducer of Human Glioblastoma Self-Destruction. In: Polson, ES, Kuchler, VB, Beard, HA, Ross, E, Markowetz, F, Zhu, S and Wurdak, H, (eds.) EMBO Chemical Biology symposium proceedings 2016. EMBO Chemical Biology Symposium 2016, 31 Aug - 03 Sep 2016, Heidelberg, Germany. EMBO .

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Identification of the Molecular Target of an Inducer of Human Glioblastoma Self-Destruction

<u>Robin S. Bon,</u>¹ Euan S. Polson,¹ Verena B. Kuchler,¹ Hester A. Beard,¹ Edith Ross,² Florian Markowetz,² Shoutian Zhu,³ and Heiko Wurdak^{1*}

Glioblastoma multiforme (GBM) is the most malignant form of brain cancer in adults with a very poor prognosis despite treatment. [1] The development of novel therapies for GBM is challenging due to its infiltrative nature, the heterogeneous and adaptive/drug-resistant character of GBM cells, and the blood brain barrier. [2] We discovered that the brain-penetrable small molecule KHS101 [3] selectively induces the self-destruction of molecularly-diverse, human patient-derived GBM cells by targeting specific metabolic vulnerabilities. Moreover, KHS101 is effective in orthotopic xenograft models.

We identified the molecular target of KHS101 in GBMs through a combination of gene expression profiling/'connectivity mapping', metabolomics, and chemical proteomics. For the latter, we used a biologically active photo-reactive benzophenone probe (KHS101-BP). Photocrosslinking experiments using KHS101-BP in life cells allowed us to identify a molecular target with direct relevance to KHS101-induced GBM self-destruction. We subsequently developed KHS101 analogues and derivatives incorporating biotin or a fluorophore to enable biophysical characterisation of the interaction between KHS101 and its protein target. These tools may allow the development of assays for rapid screening/optimisation of new compounds for the treatment of GBM.



[1] M. Preusser, S. De Ribaupierre, A. Wohrer, S. C. Erridge, Monika Hegi, M. Weller, and R. Stupp, Neurol. Prog., 2011, 70, 9–21.

[2] S. K. Carlsson, S. P. Brothers, and C. Wahlestedt, EMBO Mol. Med., 2014, 6, 1359–1370.

[3] H. Wurdak, S. Zhu, K. Hoon, L. Aimone, L. L. Lairson, and J. Watson, Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 16542–22360.